Federal Judge’s Ruling Deals Blow to Quest for Drug Price Transparency
In yet another clear sign of Big Pharma’s desire to deceive consumers, three of the world’s largest drugmakers sued—and won—to halt a rule that would require more transparency in drug pricing. The rule would have compelled pharma companies to prominently include the wholesale cost of their drugs on any television advertising, but a federal judge earlier this month struck it down.
AARP: Specialty Drug Costs Greatly Exceeding Median U.S. Household Income
Imagine that you’ve spent your entire life taking good care of yourself. You don’t abuse alcohol or drugs. You don’t smoke cigarettes. You watch what you eat and exercise regularly. You even buckle your seatbelt before you leave the driveway. But despite all those precautions, tragedy strikes, and you find yourself sick. Oh, and it turns out that the annual cost of the medication you need might be more than you make in a year.
Pharma Company Increases Drug Price by 909% as Wholesale Rates Soar
There have been plenty of times where we didn’t think Big Pharma could sink any lower. For instance, remember how the average oncology drug for cancer patients doubled in cost from 2006 to 2015? Then there was the time 20 drugmakers were found to be participating in a coordinated price-gouging scheme. And we’re sure that no one has forgotten that pharma dollars were directly linked to opioid deaths. Now comes word of a new contender in the question of just how low can they go?
New Analysis Finds Drug Costs Increasing Five Times Faster than Inflation
If you’ve spent any time outside lately, you can surely attest to the fact that we’ve reached the dog days of summer, a period that signifies we’re officially more than halfway through the year. But as we take a moment to pause in reflection of the state of healthcare across the country, we can’t help but bemoan the fact that the temps in the forecast aren’t the only things rising.
With Humira Patent Nearing its End, AbbVie Merges with Botox Maker to Keep Cash Flowing
We already know that drugmakers will do whatever it takes in order to ensure their drugs remain priced sky-high and that competition is scarce. The “pay-for-delay” ploy, a strategy in which drugmakers will pay other manufacturers to delay the marketing of a generic competitor, is nothing short of bribery. Manufacturers will also frequently use another tactic involving the use of patents to extend their dominance in the market. But perhaps the most effective means of stifling competition—and probably the most expensive and ruthless—is via mergers and acquisitions.
President Trump Signs New Executive Order Paving the Way for Better Kidney Care
If you needed regular treatment aimed at saving your life, would you rather undergo it in a cold and unpleasant facility or in the comforts of your home? The answer is obvious, which is why so many people are celebrating the recent announcement from the Trump administration on revolutionizing kidney care. Earlier this month, the president signed an executive order that focused on three areas experts feel will have a significant impact on kidney care in this country.